Contact information
merryn.voysey@paediatrics.ox.ac.uk
+44 (0)1865 611314
Oxford Vaccine Group, CCVTM, Churchill Rd, Headington, Oxford, OX3 7LE
Research groups
Merryn Voysey
Associate Professor of Statistics in Vaccinology
Merryn Voysey is Associate Professor of Statistics in Vaccinology at the Oxford Vaccine Group. She has extensive experience in vaccines research including clinical trials and observational studies, and was the lead methodologist for the Oxford-AstraZeneca vaccine trials.
She is the Principal Investigator on studies of measles seroprevalence in infants, the timing of measles vaccination in Ugandan infants, the contribution of T-cell immunity in protection against SARS-CoV-2, correlates of protection for group B streptococcus vaccines, and pneumococcal vaccine seroefficacy.
Merryn Chairs the Athena Swan Data Committee
Key publications
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2020), Lancet
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
-
Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal
Journal article
Shakya M. et al, (2019), New England Journal of Medicine, 381, 2209 - 2218
Recent publications
-
A novel approach for estimating vaccine efficacy for infections with multiple disease outcomes: application to a COVID-19 vaccine trial
Preprint
Williams LR. et al, (2023)
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
Journal article
EWER K., (2023), Clinical and Experimental Immunology
-
Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data.
Journal article
Liang Y. et al, (2022), Lancet Glob Health
-
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2022), Nat Med
-
Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Journal article
Shrestha S. et al, (2022), Lancet Glob Health, 10, e1494 - e1504